Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 16, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

[Early prostate cancer 2005. New 2005 data].

R-O Fourcade1

  • 1Service d'urologie, centre hospitalier, 2, boulevard Verdun, 89000 Auxerre, France. rfourcade@rofuro.fr

Annales D'Urologie
|March 17, 2007
PubMed
Summary

Bicalutamide shows no overall survival benefit for early prostate cancer but improves progression-free survival in locally advanced cases. It significantly benefits overall survival for radiotherapy patients with locally advanced prostate cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Perceptions of benign prostatic hyperplasia according to the perspective of patients and general practitioners - the Trophée study].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2013
See all related articles

Area of Science:

  • Oncology
  • Clinical Trials
  • Pharmacology

Context:

  • The Early Prostate Cancer (EPC) Program investigated bicalutamide's efficacy in non-metastatic prostate cancer.
  • Three randomized, double-blind, placebo-controlled trials enrolled 8113 men.
  • Participants received either bicalutamide 150 mg/day or a placebo.

Purpose:

  • To assess bicalutamide's effectiveness as adjuvant therapy or monotherapy for localized and locally advanced prostate cancer.
  • To evaluate its impact on overall survival and progression-free survival.

Summary:

  • No significant overall survival benefit was observed in localized, low-risk disease groups.
  • Adjuvant hormonal therapy with bicalutamide significantly improved objective progression-free survival in locally advanced disease.
  • Bicalutamide demonstrated a significant overall survival benefit for radiotherapy-treated patients with locally advanced prostate cancer.

Impact:

  • Adjuvant bicalutamide can be a valuable treatment option for specific prostate cancer patient groups.
  • The findings contribute to optimizing treatment strategies for locally advanced prostate cancer.
  • Further research may refine the role of bicalutamide in prostate cancer management.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Jul 16, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025